
1 5 2003 Hander the Pa	aperwork Reduction Act	of 1995, no per	sons are re	quired to respond to a collect	tion of information	on unless it displays a v	IENT OF COMMERCE valid OMB control number
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Application Number		09/854,248		
			Filing Date		May 11, 2001		
			First N	rst Named Inventor Michael Salgaller		11, 1	
			Art Unit		1614 CEN 20		
			Exami	ner Name	Gerald R. Ewoldt		11/2/7/10
Total Number of Pages in This Submission 3			Attorne	ey Docket Number	020093-000810US		
		ENC	LOSURE	S (Check all that appl	'y)		
Fee Transmittal Form		☐ Drawing(s)		After Allowance Communication to Group			
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences			
Response to Restriction Requirement		Petition		Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final		Petition to Convert to a Provisional Application			Proprietary Information		
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence Address			Status Letter		
Extension of Time Request		Terminal Disclaimer			Other Enclosure(s) (please identify below):		
Express Abandonment Request			equest for Refund D, Number of CD(s)		Return Postcard		
☐ Information Disclosure Statement							
Certified Copy of Priority Document(s)		Remarks The Commissioner is Account 20-1430.		authorized to	charge any addition	onal fees to Deposit	
Response to Missing Parts/ Incomplete Application				J			
Response to Missing Parts under 37 CFR 1.52 or 1.53		•					
	SIGN	NATURE O	F APPL	ICANT, ATTORNEY	, OR AGEN	IT	
Firm	Townsend and Townsend and Crew LLP						
or Individual	Brian W. Poor Reg. No. 32,928						
Signature	Thian	_ W.		or			
Date	July 10, 2003						
		CERTIFIC	ATE OF	TRANSMISSION/M	AILING		
I hereby certify that this co as first class mail in an en	orrespondence is being velope addressed to: Co	facsimile trans ommissioner f	mitted to t or Patents	he USPTO or deposited wi	th the United S a, VA 22313-14	tates Postal Service v 450 on the date show	with sufficient postage n below.
Typed or printed name	e Angelie River	a			• • •	·	
Signature					Date	July 10, 2003	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Glectin/#8
7.2903
TENGE

Attorney Docket No. 20093-0

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Michael Salgaller et al.

Application No.: 09/854,248

Filed: May 11, 2001

For: METHOD TO INCREASE CLASS

1 PRESENTATION OF

EXOGENOUS ANTIGENS BY HUMAN DENDRITIC CELLS

Examiner:

Gerald R. Ewoldt

Art Unit:

1644

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated June 10, 2003, which set forth the following groups of claims:

- I. Claims 1-9, drawn to a composition comprising human dendritic cells (DCs), classified in Class 435, subclass 372.
- II. Claims 10-21, drawn to a method for producing a tumor cell inhibiting response comprising administering to a patient DCs, classified in Class 424, subclass 534.
- III. Claims 22-35, drawn to a method for producing a tumor growth inhibiting response comprising administering to a patient activated T cells, classified in Class 424, subclass 93.71.

Applicants elect to prosecute Group II, claims 10-21, with traverse. Applicants reserve the right to file a divisional or related application to the subject matter encompassed by any claim of a non-elected group. Further, the Examiner has requested election of a single

Michael Salgaller *et al.* Serial No. 09/854,248 Page 2

disclosed specific antigen for continued prosecution. The Examiner has suggested election of a specific antigen listed in dependent claim 6. Applicants elect peptide PSM-P1 (SEQ ID NO: 1), an antigenic peptide from the prostate antigen PSMA (prostate specific membrane antigen) recited in claims 5 and 14 (a claim of elected Group II) for continued prosecution. Further, Applicants note that upon an indication of allowability of a generic claim, a reasonable number of additional species will be considered and can also be claimed in the same application as provided by 37 C.F.R. § 141. Claims 10-13 and 16-21 are generic to the elected species. Claim 14 contains the elected species and claim 15 does not read on the elected species of peptide antigen PSM-P1.

Applicants believe all requirements for responding to the request for restriction have been addressed. If for any reason the Examiner feels that a telephone conference would expedite prosecution of the subject application, the Examiner is invited to telephone the undersigned at (206) 467-9600.

Respectfully submitted,

Dated:

By:

Brian W. Poor

Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Ph:(206) 467-9600 Fax: (415) 576-0300

SE 5017239 v1